The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

It’s been almost four years since the U.S. Food and Drug Administration approved the first Covid-19 vaccine. Emphasis has been given to get the jab as it can help to protect you against developing ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. ("Walden”), a private, venture-backed biotechnology company advancing disease-modifying therapies to transform the ...

In the first randomized trial of its kind, researchers found that adding chemoradiation to adjuvant chemotherapy did not ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...